Publication AWA
At the Public Information Bulletin of the Agency for Health Technology Assessment and Tarification (AWA) has published review analyses for the evaluation of reimbursement applications:
- Fruzaqla (fruquintinib) in the treatment of patients with colorectal cancer
- Omjjara (momelotinib) in the treatment of patients with Ph (-) myeloproliferative neoplasms
We encourage you to read the full documents and submit comments within the prescribed period of 7 days from the date of publication.
